- Home
- NTIP vs CASI Comparison
NTIP vs CASI Comparison
Compare NTIP & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- CASI
- Stock Information
- Founded
- NTIP 1990
- CASI 1991
- Country
- NTIP United States
- CASI China
- Employees
- NTIP N/A
- CASI N/A
- Industry
- NTIP Multi-Sector Companies
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- CASI Health Care
- Exchange
- NTIP Nasdaq
- CASI Nasdaq
- Market Cap
- NTIP 32.0M
- CASI 35.8M
- IPO Year
- NTIP 1998
- CASI 1996
- Fundamental
- Price
- NTIP $1.62
- CASI $2.32
- Analyst Decision
- NTIP
- CASI Strong Buy
- Analyst Count
- NTIP 0
- CASI 1
- Target Price
- NTIP N/A
- CASI $4.00
- AVG Volume (30 Days)
- NTIP 58.3K
- CASI 411.7K
- Earning Date
- NTIP 10-23-2025
- CASI 08-29-2025
- Dividend Yield
- NTIP 6.17%
- CASI N/A
- EPS Growth
- NTIP N/A
- CASI N/A
- EPS
- NTIP N/A
- CASI N/A
- Revenue
- NTIP $150,000.00
- CASI $31,564,000.00
- Revenue This Year
- NTIP N/A
- CASI N/A
- Revenue Next Year
- NTIP N/A
- CASI N/A
- P/E Ratio
- NTIP N/A
- CASI N/A
- Revenue Growth
- NTIP N/A
- CASI 36.64
- 52 Week Low
- NTIP $1.16
- CASI $1.09
- 52 Week High
- NTIP $1.90
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- NTIP 57.28
- CASI 59.07
- Support Level
- NTIP $1.56
- CASI $2.18
- Resistance Level
- NTIP $1.65
- CASI $2.46
- Average True Range (ATR)
- NTIP 0.08
- CASI 0.24
- MACD
- NTIP 0.01
- CASI -0.02
- Stochastic Oscillator
- NTIP 42.42
- CASI 60.94
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.